| 1 |
Kahnert K, Kauffmann-Guerrero D, Huber RM. SCLC-state of the art and what does the future have in store？[J]. Clin Lung Cancer, 2016, 17(5): 325-333.
|
| 2 |
卢晓倩，孟繁杨，窦 乐，等. 肺腺癌MSCT影像特征与EGFR突变相关性分析[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(3): 319-323.
|
| 3 |
瓦热斯江·衣不拉音，吴振华，孙伟，等. 肺腺癌组织中IGF1R、Cezanne-1表达与EGFR基因突变的相关性分析[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(3): 324-328.
|
| 4 |
Zhang M, Zhou S, Zhang L, et al. Role of cancer-related inflammation in esophageal cancer[J]. Crit Revi Eukaryot Gene Expr, 2013, 23(1): 27-35.
|
| 5 |
Saini J, Sharma PK. Clinical, prognostic and therapeutic significance of heat shock proteins in cancer[J]. Curr Drug Targets, 2018, 19(13): 1478-1490.
|
| 6 |
Okada F. Inflammation-related carcinogenesis: current findings in epidemiological trends, causes and mechanisms[J]. Yonago Acta Med, 2014, 57(2): 65-72.
|
| 7 |
Inoue D, Ozaka M, Matsuyama M, et al. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan[J]. Jpn J Clin Oncol, 2015, 45(1): 61-66.
|
| 8 |
Feng J, Xie G, Zhan Y, et al. Elevated HSP90 associates with expression of HIF-1α and p-AKT and is predictive of poor prognosis in nasopharyngeal carcinoma[J]. Histopathology, 2019, 75(2): 202-212.
|
| 9 |
Niu L, Qiao W, Hu Z, et al. Berberine attenuates lipopolysaccharide-induced impairments of intestinal glutamine transport and glutaminase activity in rat[J]. Fitoterapia, 2011, 82(3): 323-330.
|
| 10 |
An JJ, Lee YP, Kim DW, et al. Transduced HSP27 protein protects neuronal cell death by enhancing FALS-associated SOD1 mutant activity[J]. BMB reports, 2009, 42(3): 136-141.
|
| 11 |
Fucarino A, Pitruzzella A. Role of HSP60/HSP10 in lung cancer: simple biomarkers or leading actors？[J]. J Oncol, 2020, 2020: 4701868.
|
| 12 |
杨银忠，张建英，程文霞，等. 血液HSP90α，CEA, NSE, CYFRA21-1及SCCA联合检测对肺癌的诊断价值研究[J]. 中国现代医学杂志，2017, 27(12): 60-64.
|
| 13 |
赛亚飞，高美丽，金发光，等. 血清肿瘤标志物CEA、CA125、CYFRA211在支气管肺癌诊断、病理类型及TNM分期中的价值分析[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(1): 34-37.
|
| 14 |
Shimomura A, Yamamoto N, Kondo S, et al. First-in-human phase i study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors[J]. Mol Cancer Ther, 2019, 18(3): 531-540.
|
| 15 |
Costa TEMM, Raghavendra NM, Penido C. Natural heat shock protein 90 inhibitors in cancer and inflammation[J]. Eur J Med Chem, 2020, 189: 112063.
|
| 16 |
刘娜斯，曹明月，吴友明，等. HSP90抑制剂抑制糖酵解并促进小鼠肝癌细胞系H22凋亡[J]. 基础医学与临床，2020, 40(7): 912-916.
|
| 17 |
陈 欣，戈海泽. 热休克蛋白90与肺癌相关性研究进展[J]. 黑龙江医学，2020, 44(8): 1157-1159.
|
| 18 |
宋 丹，郑勇斌. 热休克蛋白90在结直肠癌中的研究现状与展望[J]. 中华实验外科杂志，2022, 39(3): 418-422.
|
| 19 |
范姝婕，刘俊雅，王 俊，等. HSP90靶向抑制剂P7与多西紫杉醇联用对三阴性乳腺癌细胞的协同抗肿瘤作用[J]. 基础医学与临床，2018, 38(5): 659-663.
|